Naltrexone and β-funaltrexamine antagonism of the antinociceptive and response rate-decreasing effects of morphine, dezocine, and d-propoxyphene

Psychopharmacology

Volumn 144, Issue 1, 1999, Pages 45-53

  Walker, Ellen A ^a   Tiano, Michael J ^a   Benyas, Steven I ^a   Dykstra, Linda A ^b   Picker, Mitchell J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Funaltrexamine; d Propoxyphene; Dezocine; Efficacy; Morphine; Naltrexone

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; BETA FUNALTREXAMINE; DEXTROPROPOXYPHENE; DEZOCINE; MORPHINE; NALTREXONE; OPIATE ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RAT; RECEPTOR INTRINSIC ACTIVITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NALTREXONE; NOCICEPTORS; PAIN; RATS;

EID: 0033022314     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050975     Document Type: Article

References (55)

1. Adams JU, Paronis CA, Holtzman SG (1990) Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine. J Pharmacol Exp Ther 255:1027-1032
2. Arunlakshana O, Schild H (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58
3. Burke TF, Woods JH, Lewis JW, Medzihradsky F (1994) Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J Pharmacol Exp Ther 271:715-721
4. Butelman ER, Negus SS, Lewis JW, Woods JH (1996) Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys. Psychopharmacology 123:320-324
5. Chen JC, Smith ER, Cahill M, Cohen R, Fishman JB (1993) The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci 52:389-396
6. 2 analysis. Psychopharmacol Ser 4:107-121
7. Emmerson JL, Gibson WR, Harris PN, Todd GC, Pierce EC, Anderson RC (1971) Short-term toxicity of propoxyphene salts in rats and dogs. Toxicol Appl Pharmacol 19:452-470
8. Fiut RE, Picchioni AC, Chin L (1966) Antagonism of the convulsive and lethal effects induced by propoxyphene. J Pharmacol Sci 55:1085-1087
9. Fraser HF, Isbell H (1960) Pharmacology and addiction liability of dl- and d-propoxyphene. Bull Narcot 12:9-14
10. Gal TJ, DiFazio CA (1984) Ventilatory and analgesic effects of dezocine in humans. Anesthesiology 61:716-722
11. Gerak LR, France CP (1996) Changes in sensitivity to the rate-decreasing effects of opioids in pigeons treated acutely or chronically with nalbuphine. Behav Pharmacol 7:437-447
12. Hayes AG, Sheehan MJ, Tyers MB (1987a) Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists. Br J Pharmacol 91:823-832
13. Hayes AG, Skingle M, Tyers MB (1987b) Evaluation of the receptor selectivities of opioid drugs by investigating the block of their effect on urine output by beta-funaltrexamine. J Pharmacol Exp Ther 240:984-988
14. Izenwasser S, Newman AH, Cox BM, Katz JL (1996) The cocaine-like behavioral effects of meperidine are mediated by activity at the dopamine transporter. Eur J Pharmacol 297: 9-17
15. Kenakin TP (1997) Pharmacologic analysis of drug-receptor interactions, 3rd edn. Lippincott-Raven, Philadelphia
16. Koek W, Woods JH (1989) Partial generalization in pigeons trained to discriminate morphine from saline: applications of receptor theory. Drug Dev Res 16:169-181
17. Leander JD (1979) Effects of propoxyphene, ethoheptazine, and azabicyclane on schedule-controlled responding: attenuation by pentobarbital but not naloxone. Psychopharmacology 66: 19-22
18. Leander JD, McMillan DE (1977) Meperidine effects on schedule-controlled responding. J Pharmacol Exp Ther 201:434-443
19. Lehman T, Peterson GR (1978) Naloxone-reversible analgesic action of SKF 525-A in mice. Psychopharmacology 59:305-308
20. Malis JL, Rosenthale ME, Gluckman MI (1975) Animal pharmacology of Wy-16,225, a new analgesic agent. J Pharmacol Exp Ther 194:488-498
21. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532
22. Morgan D, Picker MJ (1998) The μ opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the μ opioid receptor. Psychopharmacology 140:20-28
23. Negus SS, Burke TF, Medzihradsky F, Woods JH (1993) Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine. J Pharmacol Exp Ther 267:896-903
24. Neil A (1982) Morphine- and methadone-tolerant mice differ in cross-tolerance to other opiates. Heterogeneity in opioid mechanisms indicated. Naunyn-Schmiedeberg's Arch Pharmacol 320:50-53
25. Neil A (1984) Affinities of some common opioid analgesics toward four binding sites in mouse brain. Naunyn-Schmiedeberg's Arch Pharmacol 328:24-29
26. Neil A, Terenius L (1981) d-Propoxyphene acts differently from morphine on opioid receptor-effector mechanisms. Eur J Pharmacol 69:33-39
27. Nickander RC, Smits SE, Steinberg MI (1977) Propoxyphene and norpropoxyphene: pharmacologic and toxic effects in animals. J Pharmacol Exp Ther 200:245-254
28. Nickander RC, Emmerson JL, Hynes MD, Steinberg MI, Sullivan HR (1984) Pharmacologic and toxic effects in animals of dextropropoxyphene and its major metabolite norpropoxyphene: a review. Hum Toxicol 3:13S-36S
29. O'Brien JJ, Benfield P (1989) Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 38:226-248
30. Overton DA, Batta SK (1979) Investigation of narcotics and anti- tussives using drug discrimination techniques. J Pharmacol Exp Ther 211:401-408
31. Paronis CA, Holtzman SG (1992) Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats. J Pharmacol Exp Ther 262:1-9
32. Picker MJ (1997) Discriminative stimulus effects of the mixed- opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther 283:1009-1017
33. Picker MJ, Yarbrough J, Hughes CE, Smith MA, Morgan D, Dykstra LA (1993) Agonist and antagonist effects of mixed action opioids in the pigeon drug discrimination procedure: influence of training dose, intrinsic efficacy and interanimal differences. J Pharmacol Exp Ther 266:756-767
34. Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson, Smith MA (1996) Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by mu, kappa and delta opioid agonists. J Pharmacol Exp Ther 279:1130-1141
35. Pitts RC, West JP, Morgan D, Dykstra LA, Picker MJ (1996a) Opioids and rate of positively reinforced behavior: differential antagonism by naltrexone. Behav Pharmacol 7:205-215
36. Pitts RC, West JP, Hapke DM, Morgan D, Dykstra LA, Picker MJ (1996b) Opioids and rate of positively reinforced behavior: II. Antagonism by β-funaltrexamine. Exp Clin Psychopharmacol 4:389-395
37. Romagnoli A, Keats AS (1984) Ceiling respiratory depression by dezocine. Clin Pharmacol Ther 35:367-373
38. Rowlingson JC, Moscicki JC, DiFazio CA (1983) Anesthetic potency of dezocine and its interaction with morphine in rats. Anesth Analg 62:899-902
39. Schaefer GJ, Holtzman SG (1981) Morphine-like stimulus effects in the monkey: opioids with antagonist properties. Pharmacol Biochem Behav 14:241-245
40. Shannon HE, Holtzman SG (1977) Further evaluation of the discriminative effects of morphine in the rat. J Pharmacol Exp Ther 201:55-66
41. Sosnowski M, Yaksh TL (1990) Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anesthesiology 73:1141-1147
42. Strain EC, Preston KL, Liebson IA, Bigelow GE (1996) Opioid antagonist effects of dezocine in opioid-dependent humans. Clin Pharmacol Ther 60:206-217
43. Takemori AE (1974) Determination of pharmacological constants: use of narcotic antagonists to characterize analgesic receptors. In: Braude M, Harris L, May E, Smith J, Villarreal J (eds) Narcotic antagonists. Raven Press, New York, pp 335-344
44. Tallarida RJ, Murray RB (1987) Manual of pharmacological calculations with computer programs. Springer, New York
45. Tiano MJ, Walker EA, Dykstra LA (1998) Cross-tolerance to etorphine differentiates μ-opioid agonists in a rat tail withdrawal assay. Analgesia 3:251-257
46. Walker EA, Young AM (1993) Discriminative-stimulus effects of the low efficacy mu agonist nalbuphine. J Pharmacol Exp Ther 267:322-330
47. 2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J Pharmacol Exp Ther 271:959-968
48. 2 analysis in rats treated with either clocinnamox or morphine. Psychopharmacology 125:113-119
49. Walker EA, Zernig G, Young AM (1998) In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay. Psychopharmacology 136:15-23
50. Yoburn BC, Shah S, Chan K, Duttaroy A, Davis T (1995) Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity. Pharmacol Biochem Behav 51:535-539
51. Young AM, Stephens KR, Hein DW, Woods JH (1984) Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. J Pharmacol Exp Ther 229:118-126
52. Young AM, Masaki MA, Geula C (1992) Discriminative stimulus effects of morphine: effects of training dose on agonist and antagonist effects of mu opioids. J Pharmacol Exp Ther 261: 246-257
53. Zacny JP, Lichtor JL, de Wit H (1992) Subjective, behavioral, and physiologic responses to intravenous dezocine in healthy volunteers. Anesth Analg 74:523-530
54. Zernig G, Butelman ER, Lewis JW, Walker EA, Woods JH (1994) In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J Pharmacol Exp Ther 269:57-65
55. Zimmerman DM, Leander JD, Reel JK, Hynes MD (1987) Use of β-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands. J Pharmacol Exp Ther 241:374-378